Drug Profile
Research programme: monoclonal antibody conjugates - Stemline Therapeutics
Alternative Names: SL-101; SL-601Latest Information Update: 15 Jun 2020
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Stemline Therapeutics
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Interleukin-3 receptor alpha subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies